Academic Background and Problem Pancreatic Ductal Adenocarcinoma (PDAC) is an aggressive cancer with an extremely low five-year survival rate, primarily due to late diagnosis and limited treatment options. Approximately 95% of PDAC patients harbor KRAS mutations, with the KRAS-G12D mutation being the most common. Although KRAS mutations have long b...